Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine.

28 Nov 2014

FDA-approved therapy could be effective in older, African American patients with lung cancer

University of Cincinnati researchers have found in a phase-2 clinical trial that a Food and Drug Administration-approved therapy could be effective in treating both older and African American patients with advanced lung cancer who may not be candidates for chemotherapy.

26 Nov 2014

Study shows effectiveness of VolitionRx’s NuQ test in detecting lung cancer in blood and sputum

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that data from its pilot lung cancer study will be presented at the Science for Business BioWin Day 2014, being held November 26, 2014 in Louvain-la-Neuve, Belgium.

25 Nov 2014

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Dacomitinib, an irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor, does not improve outcomes compared with the first-generation EGFR–TKI erlotinib in patients with advanced non-small-cell lung cancer, irrespective of their KRAS mutation status, finds the ARCHER 1009 study.

24 Nov 2014

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

23 Nov 2014

New drug shows promise against treatment-resistant non-small cell lung cancer

A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial.

23 Nov 2014

Accelerated treatment regimen feasible for advanced NSCLC

A treatment strategy designed to minimise the effects of accelerated repopulation using hypofractionated radiotherapy with chemotherapy is feasible for patients with stage III non-small-cell lung cancer, according to UK researchers.

21 Nov 2014

Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

A team led by Ludwig and Memorial Sloan Kettering (MSK) researchers has published a landmark study on the genetic basis of response to a powerful cancer therapy known as immune checkpoint blockade.

21 Nov 2014

Biomarker-directed chemotherapy detrimental in NSCLC

Treating non-small-cell lung cancer patients with chemotherapy customised according to expression of BRCA1 and receptor-associated protein 80 does not improve progression-free survival compared with nonselected, cisplatin-based chemotherapy, show study findings.

19 Nov 2014

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio AS, an oncology biopharmaceutical company, today announces that the US Food and Drug Administration has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML).

19 Nov 2014

Curcumin and tackling mesothelioma: an interview with Dr. Afshin Dowlati

An important point about this work is that the research into curcumin was conducted following a discovery about mesothelioma, rather than being the primary endpoint of the study.

17 Nov 2014

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Lobectomy may the best option for elderly patients with early-stage non-small-cell lung cancer who are able to undergo surgery, say researchers from the US.

14 Nov 2014

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show.

14 Nov 2014

Postoperative radiation benefits N2 resected NSCLC patients

Patients with resected, margin-negative non-small-cell lung cancer with mediastinal node metastases derive significant benefit from postoperative radiotherapy, US researchers report.

14 Nov 2014

Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

Pretreatment interstitial lung disease (ILD) is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT) alone.

12 Nov 2014

AZD3965 drug inhibits growth of tumours in the lab

Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.

6 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Molecular profiling reveals potential therapeutic targets for lung cancer

Analysis of 607 small cell lung cancer (SCLC) lung tumors and neuroendocrine tumors (NET) identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Small Cell Lung Cancer News and Research

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

FDA-approved therapy could be effective in older, African American patients with lung cancer

Study shows effectiveness of VolitionRx’s NuQ test in detecting lung cancer in blood and sputum

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

New drug shows promise against treatment-resistant non-small cell lung cancer

Accelerated treatment regimen feasible for advanced NSCLC

Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

Biomarker-directed chemotherapy detrimental in NSCLC

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

Curcumin and tackling mesothelioma: an interview with Dr. Afshin Dowlati

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

Postoperative radiation benefits N2 resected NSCLC patients

Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

AZD3965 drug inhibits growth of tumours in the lab

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Molecular profiling reveals potential therapeutic targets for lung cancer

Industry Focus eBook - Cell biology (5th edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News